Ria, Roberto

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 423

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 381

Characterization of Mitochondrial and Extra-mitochondrial Oxygen Consuming Reactions in Human Hematopoietic Stem Cells

Piccoli, C., Ria, R., Scrima, R., Cela, O., D'Aprile, A., Boffoli, D., Falzetti, F., Tabilio, A., & Capitanio, N. (2005) · Journal of Biological Chemistry

Redox biology and oxidative stressMitochondrial Function and Pathology

Cited by 209

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 127

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients

Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine

Multiple Myeloma Research and TreatmentsAngiogenesis and VEGF in Cancer

Cited by 40

Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?

Saltarella, I., Frassanito, M. A., Lamanuzzi, A., Brevi, A., Leone, P., Desantis, V., Di Marzo, L., Bellone, M., Derudas, D., Ribatti, D., et al. (2019) · Neoplasia

Multiple Myeloma Research and TreatmentsAngiogenesis and VEGF in Cancer

Cited by 32

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 17